Aim: In-stent restenosis (ISR) remains the major limitation of percutaneous coronary intervention (PCI), and the mechanism of ISR is neointimal growth. Higher serum total bilirubin (TBIL) inhibits the inflammatory response and the proliferation of vascular smooth muscle cells; however, the relationship between TBIL and ISR is still unclear. This study aimed to determine whether the serum bilirubin level is associated with ISR after coronary stenting in patients with coronary artery disease. Methods: This study investigated 1076 consecutive patients who underwent coronary stenting and follow-up angiography (average period: 236 days) using the Fukuoka University Hospital Registry. We used multivariate logistic regression analysis to identify independent predictors of ISR. 
Introduction
Intracoronary stent placement is a widely accepted treatment for patients with coronary artery disease (CAD), and drug-eluting stents (DES) have been shown to significantly reduce the rate of restenosis in randomized trials 1, 2) ; however, in-stent restenosis (ISR) is still a major problem even in the DES era. First, the ISR rate in patients implanted with a DES is considerable: over 10% of patients still require repeat that bilirubin acts as a potent chemical antioxidant 9) , and many epidemiological studies have subsequently reported that individuals with high-normal or justabove-normal serum total bilirubin (TBIL) have a lower incidence of coronary artery disease (CAD) [10] [11] [12] [13] [14] [15] .
Accumulated in vitro evidence now shows that bilirubin inhibits low-density lipoprotein oxidation, scavenges oxygen radicals, and restricts VSMC proliferation [16] [17] [18] . In animal models of balloon-induced vascular injury, bilirubin can block injury-induced VSMC proliferation and prevent narrowing of the vascular lumen 19) . According to these reports, bilirubin may have many pleiotropic effects and has attracted attention as a possible therapeutic approach to induce the prevention of coronary stenosis. Therefore, increased serum levels of TBIL in patients undergoing percutaneous coronary intervention (PCI) may be associated with vascular remodeling and restenosis by cell migration and inflammation; however, thus far, no studies have tested the association between TBIL and the clinical outcome after PCI in patients with CAD. In this study, we determined whether the serum level of bilirubin is associated with ISR after coronary stenting in CAD patients.
Methods

Study Population and Design
We analyzed the clinical and angiographic data of consecutive PCI patients treated from March 2003 to May 2009 using the Fukuoka University Hospital (FU) Registry. Patients who were eligible for this study were those who underwent additional coronary procedures (additional PCI or follow-up angiography) after baseline PCI. We excluded patients with major cardiac events (including death, myocardial infarction, stroke, and target lesion revascularization) within 3 months after baseline PCI and patients who lacked a measurement of TBIL before PCI. Thus, 1076 patients were included in this study. The initial assessment of the patients before PCI consisted of a medical history, physical examination, blood chemistry tests for TBIL, serum aspartate transaminase (AST), alanine transaminase (ALT) and creatinine. All blood samples were drawn in the morning of PCI after an overnight fast. All laboratory measurements were carried out at the Center for Clinical Chemistry using routine standardized methods. All patients gave written informed consent and this study was approved by the ethics committee of Fukuoka University Hospital.
Coronary Angiography and PCI Procedures
All patients underwent PCI according to current guidelines. All procedure decisions, including device selection and adjunctive pharmacotherapy, were made by the individual PCI operator. All patients received more than 100 mg aspirin and either clopidogrel (75 mg/day) or ticlopidine (200 mg/day). Aspirin was continued indefinitely and clopidogrel or ticlopidine was continued for at least 6 months. Angiographic follow-up was performed at 9 months or earlier if clinical presentation or non-invasive evaluation suggested ischemia.
Coronary angiographic measurements were performed at the angiographic core laboratory of Fukuoka University Hospital using a validated edge-detection system (CMS; Medis, Leiden, The Netherlands). Standard qualitative and quantitative definitions and measurements were used. ISR at follow-up was defined as luminal narrowing of more than 50% occurring in the segment with the stent or within a 5 mm segment proximal or distal to the stent. Late luminal loss was defined as the difference between the minimal lumen diameter (MLD) at the completion of the stenting procedure and that measured during follow-up.
Statistical Analysis
Discrete variables were reported as frequencies (percentage) and were compared using chi-square analysis or Fisher's exact test, as appropriate. Continuous variables are reported as the means standard deviation. Continuous variables were compared with Student's t test if data followed a normal distribution and with Wilcoxon's rank-sum test if data were skewed. Multiple logistic regression analysis was performed to identify independent predictors of ISR. Differences were considered significant when p 0.05 unless indicated otherwise. All statistical analyses were performed using the SAS software package (version 9.1, Statistical Analysis System; SAS Institute Inc., Cary, NC, USA).
Results
Patient Characteristics
A total of 1,076 patients were included: mean age, 66.5 years and mean follow-up period, 236 days. Patients were divided into 2 groups according to the occurrence of ISR at follow-up [non-ISR (n 735) and ISR (n 341) groups] ( Table 1) . Restenosis was observed in 31.7%. Patients with ISR were more likely to have diabetes mellitus and a lower body mass index (BMI), left ventricular ejection fraction (LVEF) and TBIL levels than patients without restenosis. They were also less likely to be treated with statins than patients without restenosis and more likely to be treated with diuretics and nitrate. With regard to angiographic variables, the ISR group showed a significantly higher rate of bifurcation, calcification, and ISR lesions, a shorter reference diameter and minimal lumen diameter, and a longer lesion length before PCI. Placement of a drug-eluting stent was seen more frequently in patients without restenosis. We also per- Patients were divided into 2 groups according to the occurrence of in-stent restenosis (ISR) at follow-up (non-ISR and ISR groups). Values are the means S.D. Renal insufficiency was defined as creatinine clearance calculated with the Cockcroft-Gault uquation 60 mL per min. Complex lesions were defined as lesion type B2 and C, according to the American Colledge of Cardiology/ American Heart Association. ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; QCA, quantitative coronary angiography formed sub-analysis in which we compared the patients according to stent type ( Table 2 ). As shown in Table 2 , the TBIL level in the restenosis group was significantly high in both the BMS and DES groups.
Relationship between Serum TBIL Levels at Baseline and ISR Rate at Follow-Up
As shown in Table 1 and 2, TBIL in the ISR group was significantly lower than those in the non-ISR group, and we divided the study population into 4 groups according to their TBIL level before PCI to identify the relationship between the TBIL level and the ISR rate at follow-up ( Table 3 ). The normal TBIL value at our University Hospital is 0.3 mg/dL to 1.2 mg/dL; therefore, our "low bilirubin group" was defined as TBIL 0.30 mg/dL, the "low-normal bili- rubin group" was defined as 0.75 ≥ TBIL ≥ 0.30 mg/ dL, the "high-normal bilirubin group" was defined as 1.20 ≥ TBIL ≥ 0.76 mg/dL, and the "high bilirubin group" was defined as TBIL 1.20 mg/dL. The clinical and angiographic characteristics were compared among the groups. There were no significant differences among the 4 groups regarding age, gender, the prevalence of hypertension and dyslipidemia. TBIL levels were significantly associated with BMI, LVEF, the prevalence of diabetes mellitus and renal insufficiency, serum levels of AST and ALT, and the use of ACE inhibitor/ARB, calcium channel blocker and beta blocker; however, a strong association was only detected between the rate of ISR before PCI and TBIL levels at baseline.
Angiographic outcomes at follow-up are shown in Fig. 1 . There was a significant trend for a stepwise decrease in the rate of ISR corresponding to the increase in TBIL (low bilirubin group 31.0, low-normal bilirubin group 32.3, high-normal bilirubin group 22.1, and high bilirubin group 5.6%, respectively; p 0.0083 for trend). We also performed subanalysis that divided the patients into 2 groups according to the presence or absence of suspected liver injury (Fig. 2) . Patients with suspected liver injury were defined as those who met at least one of the following criteria: AST 32 IU/mL, ALT 30 IU/mL and hepatitis B or C virus-positive. There is a correlation between TBIL levels (per category) and ISR in the absence of hepatic injury. In addition, TBIL levels (per category) tended to be associated with ISR regardless of the presence of hepatic injury.
Predictors of ISR at Follow-Up
Logistic regression analysis was used to assess independent predictors of ISR at follow-up. All factors that correlated with ISR or TBIL (Table 1 and 3) and variables that were considered to be of clinical importance (age, gender, hypertension, and dyslipidemia) were included in the univariate logistic model ( Table 4) . Next, we performed multiple logistic regression analysis that included all significant (p 0.05) univariate predictors of ISR, as shown in Table 4 , and the odds ratio and p value were adjusted for age and gender ( If the "low bilirubin group" is considered as a reference category, the "high-normal bilirubin group" and "high bilirubin group" had a significantly lower relative risk of restenosis, while the "low-normal bilirubin group" was not associated with superior risk reduction ( Table 6) .
Discussion
In the present study, we found that TBIL levels were associated with the occurrence of restenosis after PCI. Patients with high or high-normal levels of TBIL exhibited a lower rate of ISR at follow-up than patients with low TBIL. Furthermore, the risk reduction was comparable to those of other known ISR risk factors and covariates. To the best of our knowledge, this is the first report to demonstrate that serum TBIL levels before PCI serve as an independent predictor of ISR.
Several experiments have shown how bilirubin acts as an antioxidant. Stocker et al. reported that both unconjugated bilirubin and conjugated bilirubin scavenged peroxyl radicals and protected against the oxidation of low-density lipoprotein 9, 17) . With regard to its antioxidant mechanism, it is believed that bilirubin can neutralize radicals by donating a hydrogen atom, and all forms of bilrubin have this ability, including free unconjugated bilirubin, albumin-bound unconjugated bilirubin, and conjugated bilirubin. Excess proliferation of VMSCs is considered a major pathological mechanism of ISR and bilirubin can also restrict VSMC proliferation. Ollinger et al. reported that bilirubin suppressed the smooth muscle cell cycle via inhibition of the mitogen-activated protein kinase signal transduction pathways and caused p53-dependent cell cycle arrest by hypo-phosphorylation of the retinoblastoma tumor suppressor protein in VSMC 18, 19) . The pathological mechanism of ISR with a DES has not yet been sufficiently elucidated; however, some intravascular ultrasound studies of restenosis after SES implantation have shown an increase in intimal growth in a SES restenosis group as well as in a BMS group 20) . Various factors, such as calcified lesion, bifurcation lesion and stent fracture etc., might be involved in ISR with a DES [21] [22] [23] . ISR also includes stent-edge restenosis. Local drug delivery may be impaired in this case and, as a result, ISR may occur; thus, neointimal hyperplasia may be the main cause of ISR with a DES. In this study, bilirubin levels were associated with ISR in both the BMS and DES groups ( Table 2 ), and therefore a high level of TBIL may protect against ISR with a DES through the inhibition of neointimal growth, as with a BMS.
Some epidemiological studies have shown that individuals with Gilbert syndrome or uridine diphosphate-glucuronosyltransferase 1 and its polymorphism, which is related to Gilbert syndrome, were associated with a marked reduction in CAD risk 14, 15) . Although Abbreviations as in Table 1 . "low bilirubin group" was defined as TBIL 0.30 mg/dL, "low-normal bilirubin group" was difined as 0.75 ≥ TBIL ≥ 0.30 mg/dL, "high-normal bilirubin group" was defined as 1.20 ≥ TBIL ≥ 0.76 mg/dL, and "high bilirubin group" was defined as TBIL 1.20 mg/dL. ORs and p value were adjusted for age, gender. Reference category. Abbreviations as in Table 1 . P value and ORs were adjusted for age and gender. these conditions are congenital, it is unknown whether higher TBIL as an acquired condition, such as due to hepatic injury or medication, is also associated with a reduction in risk. In the present study, we examined all of the subjects together regardless of the presence of hepatic injury. AST and ALT levels were significantly associated with the serum TBIL level (per category) in this study; however, AST and ALT were not associated with ISR at follow-up. It is possible that liver dysfunction could be associated with many factors, such as increased estrogen. As this result shows (Fig. 2) , TBIL levels (per category) tended to be associated with ISR regardless of the presence of hepatic injury. This might suggest that higher TBIL might be associated with ISR reduction not only in patients with an inherent predisposition but also in patients with an acquired condition. In an animal model, TBIL increased after exogenous biliverdin administration and this prevented the formation of intimal hyperplasia 24) . Therefore, while bilirubin levels are currently a natural factor, in the future, therapeutic intervention with regard to the bilirubin level may be an effective treatment strategy for patients in need of coronary stenting. Furthermore, our results show that slightly high TBIL is required for risk reduction in humans; thus, we believe that our findings support such a future therapeutic intervention.
However, there is little evidence that bilirubin has such an effect in humans. Heme oxygenase (HO) is a rate-limiting enzyme in the degradation of heme into biliverdin, which is rapidly converted to bilirubin. Its inducible isoform, HO-1, is a stress-responsive protein that acts as an atherogenic and inflammatory mediator via its reaction products 25) . Previous studies have reported that the HO-1 polymorphism is associated with restenosis after stenting or balloon angioplasty 26, 27) . In these reports, the length polymorphism of a GT repeat in the HO-1 promoter region was shown to be an independent risk factor for restenosis, and carriers of short alleles had a reduced risk for restenosis. In addition, other reports showed that carriers of short alleles in the HO-1 gene had higher TBIL levels than non-carriers 25, 28, 29) . On the other hand, a recent study in a large population showed that the GT repeat polymorphism had no effect on restenosis 30) . Even though TBIL levels were not described in this report, this result may contradict our findings; however, while the genotype distribution of the GT repeat polymorphism was similar in Caucasian and Chinese populations, the effect of this polymorphism on TBIL levels differed according to race 25, 29) . Our present findings and these controversial data from previous studies indicated that a large proportion of restenosis after coronary stenting may be associated with the TBIL level itself but not the genotype of the HO-1 promoter region.
HO-1 gene promoter is also associated with increased high-density lipoprotein (HDL) cholesterol 25) . Low serum HDL cholesterol is one of the strongest predictors of coronary risk. HDL has been reported to take up cellular cholesterol from the periphery and to mediate the transport of excess cholesterol to the liver. Although higher HDL cholesterol prevents ISR after PCI, there were no differences in serum HDL cholesterol between the non-ISR and ISR groups or among the 4 categories according to the TBIL level (data not shown).
Our study also showed that TBIL levels are associated with the prevalence of diabetes mellitus and CKD. While TBIL levels were not correlated with diabetes mellitus in middle-aged British men 12) , in a Chinese population, a decrease in the TBIL concentration was significantly associated with an increase in glycated hemoglobin 31) . Regarding the relationship between TBIL and CKD, although TBIL levels were not correlated with renal insufficiency in this report, a previous report indicated that mildly elevated TBIL levels were negatively associated with the incidence of end-stage renal disease with IgA nephropathy, and bilirubin treatment was shown to improve the glomerular filtration rate (GFR) after ischemia/reperfusion injury of the kidney 32) . Fukui et al. demonstrated a positive correlation between the TBIL concentration and the estimated GFR in Japanese diabetic patients, and suggested that TBIL may play a role in diabetic nephropathy 33) . Meanwhile, in a US adult population, increasing levels of TBIL were independently associated with decreasing estimated GFR and increasing albuminuria 34) . Thus, bilirubin levels are not likely to have significant effects in all subjects as their effects may depend on the presence of diabetes mellitus or the cause and stage of CKD, and our results partly support this hypothesis.
Study Limitations
The present study presents a "real-world'' evaluation of independent predictors of ISR after coronary stenting, but our study had some limitations. First, we conducted a single-center, retrospective study and patient selection bias might have occurred, since only patients who underwent the follow-up coronary angiography were enrolled. Second, the sample size was relatively small. Nonetheless, we were able to demonstrate a relationship between serum TBIL levels and the rate of ISR after coronary stenting. Third, we tried to control for baseline imbalances by a multivariate model. However, these limitations still permit the interpretation of "real-world'' data taken from a routine clinical practice. Further studies are required to evaluate this issue.
Conclusions
To the best of our knowledge, this report is the first to demonstrate that the TBIL level may independently predict the risk of ISR after PCI. Patients with higher TBIL had a lower risk of ISR than those with lower TBIL. These findings present important clinical implications for identifying risk after coronary stenting. We should pay more attention to monitoring patients with lower TBIL after stenting. Furthermore, while the TBIL level is currently a completely natural factor, our results suggest that it may become a target for future therapeutic intervention.
